These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22842332)

  • 1. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.
    Cowan AJ; Seldin DC; Skinner M; Quillen K; Doros G; Tan J; O'Hara C; Finn KT; Sanchorawala V
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1935-8. PubMed ID: 22842332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
    Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
    Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
    Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.
    Leung N; Leung TR; Cha SS; Dispenzieri A; Lacy MQ; Gertz MA
    Blood; 2005 Nov; 106(10):3353-7. PubMed ID: 16037390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
    Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
    Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
    Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
    Quillen K; Seldin DC; Finn KT; Sanchorawala V
    Bone Marrow Transplant; 2011 Jul; 46(7):976-80. PubMed ID: 20956955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
    Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
    Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.
    Mejhert M; Hast R; Sandstedt B; Janczewska I
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.
    Hwa YL; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Kourelis TV; Gonsalves WI; Rajkumar SV; Go RS; Leung N; Kapoor P; Dingli D; Kyle RA; Russell S; Lust JA; Hayman SR; Lin Y; Zeldenrust S; Dispenzieri A
    Am J Hematol; 2016 Oct; 91(10):984-8. PubMed ID: 27341539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation.
    Katoh N; Matsuda M; Yoshida T; Yazaki M; Morita H; Sakashita K; Ikeda S
    Muscle Nerve; 2010 Jan; 41(1):138-43. PubMed ID: 19813189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.